POLICY POSITIONS
Protecting Patient Access to Treatment in Part B
IPA believes patients will face severe access challenges to care in physician offices and stand-alone infusion centers if Inflation Reduction Act (IRA) Part B payment cuts to healthcare providers are not addressed soon. Fortunately, the [...]
Commercial Payers & Patient Access Restrictions
IPA is opposed to commercial insurance companies inserting themselves into the patient-physician relationship and interfering with the decisions doctors and patients should be making together. One such example is a recent policy change by HCSC, [...]
Underwater Biosimilars
IPA supports expanding patient access to biosimilar products, which offer the potential to significantly lower costs for patients and the broader healthcare system. However, this potential is not being fully realized. Today, many physician practices [...]
Policy Positions for 2021 Rx Reform Bill
The Infusion Providers Alliance (IPA) is a leading voice for in-office and freestanding ambulatory infusion care, representing over 1,000 community-based, non-hospital providers across the United States. Our members are committed to preserving the integrity [...]
Congress Should Continue Suspension of Medicare Sequester
Suspension of the Medicare sequester is key to helping providers administer critical medicines during the COVID-19 pandemic.
The Reliable Buy-And-Bill Distribution System
Infusion centers and physician offices rely on the current, well-established “buy-and-bill” distribution system that has provided uninterrupted and reliable patient access to Part B infused drugs for decades.
Coupon Provision in Senate Finance Committee Drug Pricing Legislation
The Infusion Providers Alliance supports the Senate Finance Committee’s overall goals of lowering prescription drug costs for patients. However, the alliance is concerned that a coupon provision included in “The Prescription Drug Pricing Reduction Act of 2019” could increase out-of-pocket costs and make treatment less accessible
International Pricing Schemes Will Increase Cost and Adversely Impact Patients
As discussed above, the Infusion Providers Alliance opposes changes to the “buy-and-bill” model that puts patients at risk by unnecessarily increasing the complexity of the supply chain, creating problems with timely access and drug wastage due to changes in therapy regimen and potentially polluting the chain of custody of individual medications for patients.